Activation of MAT2A-RIP1 signaling axis reprograms monocytes in gastric cancer

Yan Zhang,1,2 Hui Yang,1,3 Jun Zhao,4 Ping Wan,5 Ye Hu,6 Kun Lv,1,3 YiRen Hu,7 Xi Yang,3,8 Mingzhe Ma 1,10,11

ABSTRACT

Background The activation of tumor-associated macrophages (TAMs) facilitates the progression of gastric cancer (GC). Cell metabolism reprogramming has been shown to play a vital role in the polarization of TAMs. However, the role of methionine metabolism in function of TAMs remains to be explored.

Methods Monocytes/macrophages were isolated from peripheral blood, tumor tissues or normal tissues from healthy donors or patients with GC. The role of methionine metabolism in the activation of TAMs was evaluated with both in vivo analyses and in vitro experiments. Pharmacological inhibition of the methionine cycle and modulation of key metabolic genes was employed, where molecular and biological analyses were performed.

Results TAMs have increased methionine cycle activity that are mainly attributed to elevated methionine adenosyltransferase II alpha (MAT2A) levels. MAT2A modulates the activation and maintenance of the phenotype of TAMs and mediates the upregulation of RIP1 by increasing the histone H3K4 methylation (H3K4me3) at its promoter regions.

Conclusions Our data cast light on a novel mechanism by which methionine metabolism regulates the anti-inflammatory functions of monocytes in GC. MAT2A might be a potential therapeutic target for cancer cells as well as TAMs in GC.

INTRODUCTION

Gastric cancer (GC) is the fourth most frequent malignancy and the third leading cause of cancer-related mortality around the world.1,2 Despite the great advances in GC screening and therapy, the prognosis of patients with GC at advanced stages remains to be dismal.3 The advent of immunotherapy has greatly changed the landscape of cancer therapy.4 Cancer immunotherapies, including immune checkpoint inhibitors and adoptive cell transfer, have demonstrated therapeutic benefits in a variety of tumors.5 However, the proportion of patients who respond to immunotherapy remains modest (about 15%) because of resistance and tumor immune evasion.6 An ideal immunotherapy for GC would be relieving immunosuppression through remodeling the tumor microenvironment (TME).5 Thus, further research on the molecular mechanisms underlying tumor immune evasion is required.

Monocytes/macrophages constitute the major component of tumor-infiltrating immune cell population.7 Monocytes/macrophage are commonly educated by the TME and promote tumor progression via diversified mechanisms, including immune evasion.7–9 Previous studies have demonstrated that GC is highly infiltrated with monocytes with activated phenotype (mainly M2 subtype).10–12 The functional phenotype of monocytes/macrophage can be influenced by surrounding milieu.7–9 However, the underlying molecular mechanisms are largely unclear.

A growing volume of literature have demonstrated the important role of cell metabolism in the activity and function of immune cells, including macrophage,13–15 T cells16,17 and dendritic cells.18,19 Two main subtypes of macrophages have been defined with distinct metabolic profiles.20 The anti-inflammatory M2 macrophage is characterized by increased oxidative phosphorylation and fatty acid oxidation, while the classical proinflammatory M1 macrophage is characterized by enhanced glycolysis.21 These metabolic characteristics have been shown to be vital in sustaining the functional phenotypes of macrophages; however, the precise molecular mechanism remains to be explored.21

Cell metabolism provides energy and material basis for cellular signaling transduction.13 Methionine, an essential amino acid, has been shown to play a vital role in the maintenance of stemness of embryonic22 and pluripotent stem cells23 as well as carcinogenesis.24 S-adenosylmethionine (SAM) is generated from methionine by a family of conserved methionine adenosyltransferase (MAT) enzymes. The catalytic subunits of MAT enzymes are...
derived from two genes, the ubiquitously expressed methionine adenosyltransferase II alpha (MAT2A) genes and the liver-specific MAT1A. There has been an established link between methionine adenosyltransferases and the progression of cancer, including GC. However, whether MAT enzymes are also involved in tumor-associated macrophage (TAM) polarization remains unknown. Interestingly, Covarrubias et al performed unbiased metabolic profiling of M2 macrophages and found that methionine metabolism was among the top enriched pathways. This bioinformatics analysis result makes us consider the effects of methionine metabolism on TAM. SAM is a major biological methyl donor, which is required for methylation. Recent studies have shown that epigenetic modifications, including acetylation and methylation, modulate the polarization and activation of macrophages. While much attention has been paid to the effect on glycolysis and lipid metabolism in the macrophage, little is known about the role of its methionine metabolism.

In this study, we have found that the upregulated MAT enzyme MAT2A regulates the cellular SAM levels and histone methylation pattern in monocytes/macrophages. MAT2A epigenetically induces RIP1 expression and a protumor phenotype in macrophages.

MATERIALS AND METHODS

Patients and clinical samples

The study was censored by the Clinical Research Committee of Yijishan Hospital, Wenzhou People’s Hospital and the Fudan University Shanghai Cancer Center. The GC tissues were confirmed pathologically. A cohort of patients involving 42 paired blood samples, GC tissues and normal tissues were obtained from Yijishan Hospital who underwent surgery in Yijishan Hospital between June 2019 and October 2019 (n=32) and October 3, 2020 and October 17, 2020 (n=4 from Yijishan Hospital, n=6 from Wenzhou People’s Hospital). These samples were used for the purification of peripheral blood-infiltrating and tumor-infiltrating leukocytes. Written consent was obtained from all patients. All of these patients were preoperative chemotherapy or radiotherapy naive. No data that could identify patients were provided. Blood samples were collected from 31 healthy donors who worked at Yijishan Hospital. Heparin tubes (BD Biosciences, San Jose, California, USA) were used for the collection of blood samples, and all blood-related experiments were carried out with fresh cells. The clinical-pathological characteristics of the patients with GC in this study are provided in online supplemental table S1.

Isolation of monocytes from peripheral blood and tissue samples

Leukocytes were isolated from the peripheral blood using Ficoll density gradient centrifugation assay (AS1114547; Axis-Shield) as previously described. GC tissues or paired normal tissues were cut into small pieces and digested in RPMI 1640 (HyClone, Invitrogen, Camarillo, California, USA) supplemented with 20% fetal bovine serum (FBS, HyClone, Invitrogen, Camarillo, California, USA), 0.05% collagenase IV (Sigma, St. Louis, Missouri, USA) and 0.005% DNase I (Roche Diagnostics, Indianapolis, Indiana, USA) for 1 hour at 37°C. The dispersed monocytes were filtered through anylon mesh of 150 mm pore size and separated by Ficoll centrifugation. The obtained monocytes were washed with phosphate buffered solution (PBS) three times and resuspended in RPMI 1640 supplemented with 10% FBS. CD14+ monocytes and autologous T lymphocytes were isolated using magnetic beads (130-050-201/130-095-130, Miltenyi Biotec, Bergisch Gladbach, Germany) following the manufacturer’s instructions and further verified for CD14 expression using flow cytometry analysis with a purity of >88% CD14+.

Preparation of methionine starvation medium

Methionine starvation media were generated from RPMI 1640 powder (US Biomedical) lacking methionine as described previously.

Preparation of tumor culture supernatants (TSNs) from gastric cancer cells and tumor-conditioned monocytes

The origin and characterization (including DNA fingerprinting, cell vitality and mycoplasma detection) of human gastric cancer cell lines (BGC823 and MGC803) used in this study were performed as described previously. The latest cell characterization was performed in September 2019. TSNs were prepared as described previously. 5×10^6 GC cells in 10 mL Dulbecco’s modified Eagle’s medium (DMEM, Gibco BRL, Grand Island, New York, USA), were seeded into 100 mm tissue culture dishes for 24 hours thereafter changing the medium to complete medium supplemented with 10% FBS (HyClone, Invitrogen, Camarillo, CA, USA).

The supernatant was then collected, centrifuged (10,000 g, 15 min) and stored in aliquots at −80°C.

In vitro culture of monocytes

Purified CD14+ monocytes were cultured in DMEM supplemented with 10% FBS in the presence or absence of 30% TSN. In some cases, purified CD14+ monocytes were treated with medium or TSN in the presence or absence of FIDAS-5 (10 µM, Merck Millipore, USA), RIP1 inhibitor (GSK547, 50 nM, GlaxoSmithKline, Brentford, UK).

In other experiments, monocytes were pretreated with DMSO, 2-amino-bicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH) (5 mM, Sigma, St. Louis, Missouri, USA), Trichostatin A (TSA) (200 ng/mL, Sigma, St. Louis, Missouri, USA), chaetocin (0.5 µM, Sigma, St. Louis, Missouri, USA), OICR-9429 (5 µM, Sigma, St. Louis, Missouri, USA), BIX-01294 (5 µM, Sigma, St. Louis, Missouri, USA), OG-L002 (50 µM, Sigma, St. Louis, Missouri, USA) and DZNep (1 µM, Sigma, St. Louis, Missouri, USA) for 1 hour before their exposure
to medium or TSN for indicated times. In some cases, monocytes were transfected with desired siRNA before exposure to medium or TSN.

**ELISA**

The concentration of the cytokines in the culture supernatants of monocytes was determined with the ELISA assay following the manufacturers’ instructions (eBioscience, Santiago, California, USA).

**Coculture of monocytes and T cells**

The coculture of monocytes and T cells was performed as described previously. The CD14+ cells purified from peripheral blood of healthy donors were treated with medium or TSN for 24 hours. Then, the CD14+ cells were washed with PBS three times and cocultured with autologous T cells at a 1:2 ratio for 24 hours. They were cultured in DMEM supplemented with anti-CD3 (2 µg/mL) and anti-CD28 antibodies (2 µg/mL).

**RNA and protein extraction, real-time qPCR analysis, western blot analysis and chromatin immunoprecipitation (ChIP)**

RNA and protein extraction, real-time qPCR analysis, western blot and ChIP analysis were performed as described previously. Primers used in this study are provided in online supplemental table S3. Information about antibodies is provided in online supplemental table S4.

**UPLC-MS analysis**

Untargeted liquid chromatograph-mass spectrometer (LC-MS) analysis of polar metabolites was performed by using an ultra performance liquid (UPLC) system (ACQUITY, Waters) interfaced with a mass spectrometer (LTQ-Orbitrap, Thermo Scientific) as described previously. Elution conditions for LC/MS analysis are provided in online supplemental table S5. Optimized compound-dependent MS parameters are provided in online supplemental table S6.

**Tumor cell apoptosis assay**

CD14+ cells purified from the peripheral blood were treated with medium (MO) or TSN (TMO) for 24 hours in the presence or absence of MAT2A inhibitor FIDAS-5 (10 µM, Merck Millipore, USA). The monocytes were then washed with cold PBS three times and exposed to autologous CD8+ T cells (with a 1:2 ratio) for 24 hours. These cells were collected and cocultured with Carboxyfluorescein diacetate, succinimidyl ester (CSFE)-labeled MGC803 cells (with a 10:1 ratio) for 12 hours. Flow cytometry assay was used to determine the apoptosis of tumor cell.

**Quantitative histone methylation proteomics**

Quantitative histone methylation proteomics were performed as described previously.

**Plasmid construction and cell transfection**

Plasmid construction and cell transfections were performed as described previously.

**Cell viability assay**

Cell viability was determined with the Cell Counting Kit 8 (CCK-8, Donjindo).

**In vivo experiments**

Nude mice (age 4–5 weeks) were purchased from the Shanghai Experimental Animal Center of the Chinese Academy of Sciences, Shanghai, and housed in a pathogen-free facility in the Experimental Animal Centre of Vijishan Hospital. All animal experiments of laboratory animals were performed by the Guide for the Care and Use published by the US NIH (NIH publication number 85–23, revised 1996). 1×10⁶ MGC803 cells in 0.1 mL PBS were injected subcutaneously into unilateral flank areas of nude mice. 5×10⁶ purified autologous T cells conditioned with monocytes or TSN treated monocytes in the presence or absence of MAT2A inhibitor were subsequently injected into the peritoneum in 0.1 mL PBS every 5 days 1 day after inoculation. Tumor growth was determined every 5 days for 30 days using calipers fitted with a vernier scale. Then, tumor-bearing mice were sacrificed. The tumors formed were surgically removed and weighed. The length (L) and width (W) were measured with calipers, and tumor volumes were calculated using the following formula: (L×W²)/2.

**Statistical analysis**

All statistical analyses were performed using SPSS software (V.17.0, Chicago, Illinois, USA). All data are presented as the mean±SD from three independent repeats. The correlation between MAT2A and RIP1 expression levels was evaluated with Spearman rank correlation test. The differences between two groups were analyzed using the Student’s t test. P values were two-sided, and a value of <0.05 was considered to be statistically significant.

Detailed descriptions of Materials and methods can be found in the online supplemental file 2.

**RESULTS**

**Tumor-infiltrating monocytes/macrophages in GC had enhanced level of methionine cycle activity**

To explore the role of methionine metabolism in GC, we determined the expression of a panel of genes involved in the methionine metabolism (online supplemental figure S1A) with qRT-PCR in CD14+ cells purified from tumor tissues and peripheral blood of 15 patients with GC (online supplemental table S2). We found that the key methionine metabolism-related genes (SHMT2, MAT2A, MTHFR, MTR) were significantly dysregulated in CD14+ cells purified from GC tissues compared with that from paired peripheral blood in 15 patients with GC (figure 1A). Among the key methionine metabolism-related genes, MAT2A was consistently upregulated and demonstrated the highest fold-change. A significant correlation between MAT2A expression in CD14+ cells purified from GC tissues and from paired peripheral blood was observed (r²=0.592, p<0.001, online supplemental figure...
Moreover, CD14+ cells isolated from tumor tissues had elevated levels of methionine, Sadenosyl methionine (SAM) and S-adenosyl homocysteine (SAH) (figure 1B), and the ratio of SAM to methionine (the indicator of the capacity for methylation reactions) was increased in CD14+ cells derived from tumor tissues (figure 1B). To further characterize the phenotype of monocytes purified from GC tissues, we used CD86 (M1 marker) and CD163 (M2 marker). 10–12 We found that the costimulatory molecule CD86 was almost absent, while strong appearance of CD163 was observed in monocytes isolated from GC tissues, indicating an overwhelming majority of the M2 phenotype. However, the expression of CD163 was significantly downregulated in CD14+ cells purified from peripheral blood of healthy donors (online supplemental figure S1C). To further investigate the role of methionine cycle metabolites in the function of the tumor-infiltrating monocytes/macrophages, we exposed the CD14+ cells purified from GC tissues to transient 48 hours methionine starvation. The methionine starvation for 48 hours reduced methionine cycle activity, as exemplified by a drastic decrease in SAM levels and a slight decrease in SAH levels (figure 1C). Forty-eight hours methionine starvation led to a significant decrease in the expression of M2 phenotype-related genes. However, the expression of CD163 was significantly downregulated in CD14+ cells purified from peripheral blood of healthy donors (online supplemental figure S1C). To further investigate the role of methionine cycle metabolites in the function of the tumor-infiltrating monocytes/macrophages, we exposed the CD14+ cells purified from GC tissues to transient 48 hours methionine starvation. The methionine starvation for 48 hours reduced methionine cycle activity, as exemplified by a drastic decrease in SAM levels and a slight decrease in SAH levels (figure 1C). Forty-eight hours methionine starvation led to a significant decrease in the expression of M2 phenotype-related genes.
of M2 genes (Mgl2, Ym1 (Chi3I3), Relma (Fizz1), Arg1 (-marginally significant, p=0.045)), while CD36 and FABP4 were not affected or even inducible (figure 1D). It is worth noting that shorter-term starvation (24 hours) was sufficient to induce significant change in the expression of M2 genes (Mgl2, Ym1 (Chi3I3), Relma (Fizz1)) (online supplemental figure S1D), which highlighted the dependence of TAM on methionine. Furthermore, there was no significant difference in cell viability after 48 hours methionine starvation (online supplemental figure S1E).

To further clarify the role of methionine cycle activity in the maintenance of the phenotype of tumor-infiltrating macrophages, we attempted to rescue the methionine-starved cells with homocysteine (Hcy, 250 µM), SAM (500 µM) or non-starvation reversal. As would have been anticipated, homocysteine supplementation (250 µM) was unable to attenuate the effects of methionine starvation, which suggested that tumor-infiltrating monocytes/macrophages required exogenous methionine for phenotype maintenance (figure 1E). SAM supplementation strategy was used to bypass the requirement of methionine for tumor-infiltrating macrophages. The downregulation of M2 genes induced by methionine starvation was greatly ameliorated with SAM supplementation (500 µM) (figure 1E). However, the attenuation level of M2 gene expression when macrophages were recovered in complete medium was not as dramatic as that with SAM supplementation (figure 1E). Surprisingly, we found that while methionine starvation markedly decreased the production of IL-10 and TGF-β, SAM supplementation significantly rescued the production of IL-10 and TGF-β in tumor-infiltrating monocytes/macrophages (figure 1F).

MAT2A modulates methionine metabolism-induced RIP1 expression on monocytes

To further confirm the relationship between increased methionine cycle activity and cancer microenvironment, we treated with monocytes purified from healthy peripheral blood with GC cell line MGC803 derived tumor cell supernatants (TSN). TSN treatment resulted in significantly enhanced levels of SAM, SAH and SAM:methionine ratio compared with those in the control medium-treated monocytes (figure 2A). TSN-exposed monocytes also demonstrated higher transcripts levels of key methionine metabolism-related genes (figure 2B). As anticipated, TSNs derived from BGC823 cells markedly increased the intracellular levels of SAM, SAH and SAM:methionine ratio (online supplemental figure 2A).

As TAMs have been reported to promote immune escape within the cancer microenvironment via diverse mechanisms, we would like to explore the role of methionine metabolism in TAM-associated antitumor immunity. TSN induced marked upregulation of Mgl2, Ym1 (Chi3I3) and Relma (Fizz1) (figure 2C) as well as IL-10 and TGF-β production (figure 2D), while transient methionine 24 hours starvation before TSN treatment significantly blunted the effects of TSN (figure 2C,D). As expected, SAM supplementation attenuated the suppressive effect of methionine starvation (figure 2C,D). Furthermore, the expression of amino acid transporter SLC7A5 was increased on TSN treatment (figure 2E). The competitive blocker for system L transporters (BCH, 5 mM) significantly blunted the promoting effects of TSN on Mgl2, Ym1 (Chi3I3) and Relma (Fizz1) (figure 2F).

Among the key methionine metabolism-related genes dysregulated in tumor-infiltrating or TSN-exposed monocytes, MAT2A demonstrated the highest fold-change (figure 2B). TSN increased the expression of MAT2A in a time-dependent manner, which peaked at 18 hours (figure 3A). Furthermore, TSN also induced a significant increase in the protein level of MAT2A (figure 3B). To investigate whether MAT2A played a role in the establishment of the phenotype of TAM, we treated CD14+ cells derived from normal blood with TSN in the presence or absence of MAT2A inhibitor FIDAS-5. FIDAS-5 treatment (10 µM) significantly attenuated the increase in the MAT2A protein level in TSN-exposed monocytes (figure 3C). Furthermore, we observed that the MAT2A inhibitor FIDAS-5 (10 µM) obviously downregulated the intracellular levels of SAM and SAH (figure 3D). Transient exposure to FIDAS-5 did not result in significant differences in cell viability in TSN-treated CD14+ cells (online supplemental figure 2B). As anticipated, FIDAS-5 inhibitor significantly attenuated the IL-10, TGF-β, Mgl2 and Relma (Fizz1) production/expression in/on TSN-exposed monocytes (figure 3E), while supplementation with SAM (500 µM) in the context of FIDAS-5 treatment markedly rescued the IL-10, TGF-β, Mgl2 and Relma (Fizz1) production/expression (figure 3E). To further confirm the role of MAT2A in the TAM phenotype, we employed the RNA interference strategy to modulate the expression level of MAT2A. As illustrated in figure 3F, si-MAT2A obviously abrogated the upregulation of MAT2A in TSN-exposed monocytes. MAT2A silencing led to suppression on M2 markers, which could be phenocopied by SAM supplementation (online supplemental figure 3).

As TSN treatment induced the antitumor immunity in monocytes, we then screened the reported the regulators of the immunosuppressive effects of TAM (online supplemental table S7). Among the dysregulated regulators of the immunosuppressive effects of TAM, RIP1 exhibited the most significant fold-change in TSN-exposed monocytes pretreated with MAT2A inhibitor (figure 4A). The increase in the mRNA level of RIP1 in response to TSN could be significantly attenuated by MAT2A inhibitor (FIDAS-5, 10 µM), siRNA mediated-MAT2A silencing, the competitive blocker for system L transporters (BCH, 5 mM) and transient methionine starvation. However, SAM supplementation could rescue the decrease induced by MAT2A inhibition (figure 4B,C). MAT2A suppression also abrogated the RIP1 expression on monocytes exposed to TSN from BGC823 cells (online supplemental figure 4A). Furthermore, RIP1 inhibitor (GSK547, 50 nM) obviously suppressed the upregulation/production
of M2 gene in response to TSN (online supplemental figure 4B,C). Functionally, MAT2A inhibitor antagonized the suppressive effect on the antitumor activity of autologous CD8+ T lymphocytes exerted by TSN (figure 4D,E).

Higher expression levels of MAT2A/RIP1 are correlated with a significantly poorer overall survival and progression-free survival in GC according to data from the KMPlot database (online supplemental figure 5A,B). According to data from TIMER (http://cistrome.org/TIMER/), a significant correlation between MAT2A and RIP1 expression was observed in GC (online supplemental figure 5C). Correlation results between MAT2A and RIP1 in GEPIA (http://gepia.cancer-pku.cn/) were similar to that in TIMER (online supplemental figure 5D). Such a correlation could also be found in other cancers (online supplemental figure 6A,B). A positive correlation between the transcript levels of MAT2A and RIP1 was observed in monocytes purified from GC tissues (n=32, R²=0.501, p<0.001, figure 4F).

MAT2A leads to epigenetic activation of RIP1 expression on monocytes

It was well known that cellular SAM levels could affect the histone methylation. Thus, we hypothesized that induction of MAT2A drives gene expression changes and acquisition of M2 phenotype through epigenetic activation/repression of vital regulators. To further clarify the contribution of epigenetic mechanisms, we transfected CD14+ monocytes purified from healthy peripheral blood with MAT2A to assess the changes in SAM levels and expression of M2-associated genes and regulators. The results indicated that MAT2A led to increased SAM levels and expression of RIP1, which is consistent with the hypothesis that MAT2A drives epigenetic activation of RIP1. Further studies are needed to investigate the mechanism of MAT2A-mediated epigenetic activation of RIP1 in monocytes.

Figure 2  Methionine mediates tumor-induced M2 phenotype of monocytes. CD14+ cells were isolated from peripheral blood of healthy donors. CD14+ cells were left untreated or treated with TSN from MGC803 cells for 20 hours. (A) (Left) LC-MS was used to determine the abundance of methionine cycle metabolites in CD14+ cells purified from tumor tissues 48 hours after methionine starvation. Values were normalized to that of CD14+ cells in the absence of TSN. (Right) Ratio of SAM to methionine levels in CD14+ cells. (B) The expression levels of methionine metabolism-related gene with qRT-PCR. (C,D) Levels of the M2-associated genes Relma, Mgl2, Ym1, Fabp4, Arg1 by qPCR (C) and IL-10 and TGF-β production (D) by ELISA. (E) qRT-PCR analysis of the expression of amino acid transporter SLC7A5 on TSN treatment. (F) CD14+ cells were pretreated with DMSO or system L transporters (BCH, 5 mM) for 1 hour and then were exposed to medium (Med) or TSN for 20 hours. qRT-PCR analysis of the M2-associated genes Mgl2, Ym1 (Chi3l3) and Relma (Fizz1). Data are presented as the mean±SD; *p<0.05. N=3 biologically independent experiments. SAM, S-adenosylmethionine; TSN, tumor culture supernatant.
with siRNA-MAT2A or siRNA-NC, then exposed to TSN for 14 hours, a time course for RNA stability was started after treatment with actinomycin D (0.5 mg/mL). Our data showed that the degradation rate of RIP1 appeared to be similar to MAT2A silencing (figure 5A). The CD14+ monocytes purified from healthy peripheral blood were pretreated with histone methyltransferase (HMT) inhibitor (chaetocin, 0.5 µM) or histone deacetylases inhibitor (TSA, 200 ng/mL) for 1 hour before exposure to TSN. We found that HMT inhibitor significantlyabolished the induction of RIP1 by TSN, while TSA had no such effect (figure 5B). Furthermore, chaetocin treatment greatly suppressed the induction of M2 genes induced by TSN, which directly supported the role of histone methylation in the regulation of TAM (online supplemental figure 7). Altogether, these data suggested that histone methylation might play a role in the modulation of RIP1, which was consistent with the previous studies that methionine metabolism could influence histone methylation of the epigenome.\(^{40}\)
To explore how methionine metabolism affected histone methylation in TAM, we used targeted histone proteomic analyses using a multireaction monitoring approach to quantify relative levels of histone lysine and arginine methylation. MAT2A inhibitor decreased the histone methylation at residues associated with
transcriptional modulation, including H3K4 and H3K27 trimethylation (me3) (figure 5C). Our data were consistent with the previous studies, which indicated that methionine metabolism, especially the concentration of SAM, regulated histone methylation. It mainly had effect on trimethylation at lysine-4 on histone H3 (H3K4me3) and at lysine-27 on histone H3 (H3K27me3). Immunoblot analysis confirmed that H3K4me3 and H3K27me3 were decreased with MAT2A suppression (figure 5D).

Moreover, we found high enrichment of H3K4me3 at the promoter region of RIP1 according to University of California (UCSC, Santa Cruz) Genome Bioinformatics Site (http://genome.ucsc.edu/) (figure 5E). It prompted us to determine whether it was H3K4me3 that was responsible for the transactivation of RIP1. As predicted, TSN exposure greatly increased global H3K4me3 levels in CD14+ monocytes derived from healthy peripheral blood, while MAT2A suppression, methionine starvation and system L transporters markedly decreased the H3K4me3 levels (figure 5F). SAM supplementation rescued the effects of MAT2A suppression on histone methylation (figure 5F).

WDR5, a vital component of SET/MLL (SET-domain/mixed-lineage leukemia) histone-methyltransferase complexes, played a key role in H3K4me3 and subsequent transactivation of target genes. We constructed the luciferase reporter vector containing the 5' flanking DNA fragment (~3 kbp) of RIP1 promoter region. We found that TSN treatment enhanced the luciferase activity of pGL3 enhancer plasmid of RIP1 (figure 6A). To determine the specific type of HMT that took part in the transcriptional regulation of RIP1, we pretreated monocyte cells with three pharmacological HMT/demethylases inhibitors: OICR-9429 (an inhibitor of WDR5, 5 µM), BIX-01294 (an inhibitor of G9a HMT, 5 µM), DZNep (an inhibitor of EZH2,1 µM) and OG-L002 (an inhibitor of LSD1, 50 µM). We observed that OICR-9429 treatment ameliorated the elevated luciferase activity of pGL3 plasmid of RIP1 induced by TSN exposure in monocytes (figure 6A). It indicated that WDR5 might take part in the regulation of RIP1. Furthermore, none of the TSN exposure, methionine starvation, MAT2A suppression had any significant effect on the protein level of WDR5 (figure 6B). We found that WDR5 silencing (figure 6C) abolished the effect of SAM supplementation on and RIP1 levels (figure 6D). The chromatin IP (ChIP) assay illustrated that obvious enrichment of H3K4me3 was found at the promoter region of RIP1 (figure 6E). TSN treatment greatly increased the H3K4me3 levels at the promoter region, while MAT2A suppression abolished these effects (figure 6E). SAM attenuated the effects of MAT2A suppression; however, such effects disappeared with WDR5 silencing (figure 6E). These data suggest that MAT2A leads to epigenetic activation of RIP1 expression on monocytes.

**DISCUSSION**

The polarization of monocytes/macrophages requires distinct transcriptional profiles, in which epigenetic regulation plays an important role. It is well known that cell
metabolism is vital for the polarization of macrophages. Metabolic reprogramming may support macrophage polarization by increasing uptake of certain nutrients (glutamine, glucose and lipid) and reprogramming of cellular biosynthetic and biogenetic pathways. In this study, we established a link between methionine metabolism and epigenetic reprogramming to support M2 polarization. We found that depletion of exogeneous methionine or inhibition of methionine adenosyltransferase enzyme (MAT2A) impaired the polarization of macrophages. Methylation patterns demonstrated great dependence on SAM content, with genes involved in M2 polarization showing decreased levels of H3K4me3 on the promoter region on SAM starvation. The effect of methionine metabolism on immune surveillance was confirmed by both in vitro and ex vivo findings.

There has been an established link between methionine adenosyltransferases and the progression of cancer, including GC. However, the role of methionine metabolism in TAM remains unknown. Yu et al reported that SAM generation maintains a high SAM:methionine ratio to support histone H3K36me3 for macrophage IL-1β production. The discrepancy between our study and the study by Yu et al may be due to differences in stimulation conditions (ie, lipopolysaccharide (LPS) by Yu et al). The two studies may suggest that methionine metabolism is important to the M1 and M2 polarization of macrophages. Yu et al demonstrate that MAT2A inhibitor exerts the greatest change on H3K36me3 on LPS stimulation. It is known that HMTs have different affinities for SAM. For example, due to the lower Km of H3K36me3 methyltransferase SETD2 compared with H3K4me3 methyltransferase WDR5/MLL1, H3K4me3 abundance would be lower in the competition between these enzymes for limited SAM availability. It suggests that the impact of SAM bioavailability on methylation pattern depends both on stimulation conditions and Km of HMTs.

Although this study concentrates on the effect of methionine metabolism on histone methylation pattern, it is worth noting that SAM availability affects a plethora of cellular processes, including DNA/RNA methylation, which may contribute to the M2 polarization induced by MAT2A inhibition. It is reported that SAM depletion reduced the N6-methyladenosine (m6A) in 3' Untranslated Regions (UTR) of MAT2A, leading to mRNA stabilization. To exclude the possibility that m6A might be involved in the regulation of RIP1 mRNA, we tested the effect of MAT2A silencing on the stability of RIP1 mRNA. We found that MAT2A silencing had no effect on the stability of RIP1 mRNA, thus excluding the possibility that m6A is involved in the regulation of RIP1, we tested the effect of MAT2A silencing on the stability of RIP1 transcript. Roy et al found that acute methionine starvation (6 hours) had limited impact on the level of lineage-specific transcription factors (eg, RORγt expression by Th17 cells). However, we found that methionine starvation (48 hours) suppressed the expression of M2 markers. It still requires investigation whether extended exposure (>6 hours) to methionine starvation of established Th17 cells would result in changes in methylation markers (ie, H3K4me3) that affect Th cell lineage stability.

Previous studies demonstrate that TAMs within the TME (5%-10% of the tumor stromal mass) prominently exhibit an M2-like phenotype and promote tumor growth and metastasis via different mechanisms, including tumor immune evasion. Thus, modulating macrophage
function represents an attractive approach. Inhibitors targeting MAT2A would modulate the TAM and cancer cells with high methionine metabolism rate, which would provide more ideal TMEs for chemotherapies or immune-therapies.

In conclusion, our study showed the detailed mechanistic insight of MAT2A-WDR5-R1P1 axis in TAM. This study suggests a novel cancer immune modulatory strategy.

**Author affiliations**

1. Key Laboratory of Non-coding RNA Transformation Research of Anhui Higher Education Institution (Wannan Medical College), Wuhu, China
2. Department of Gastroenterology, Yijishan Hospital, The First Affiliated Hospital of Wannan Medical College, Wuhu, China
3. Central Laboratory, Yijishan Hospital, The First Affiliated Hospital of Wannan Medical College, Wuhu, China
4. Department of General Surgery, Yijishan Hospital, The First Affiliated Hospital of Wannan Medical College, Wuhu, China
5. Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
6. State Key Laboratory for Oncogenes and Related Genes, Division of Gastroenterology and Hepatology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
7. Department of General Surgery, Wenzhou No. 3 Clinical Institute of Wenzhou Medical University, Wenzhou People’s Hospital, Wenzhou, China
8. Shanghai Institute of Head Trauma, Shanghai, China
9. Department of Neurosurgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
10. Department of Gastric Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
11. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

**Correction notice** This paper has been updated since first published to amend author name ‘Kun Lv’. Additionally, the provenance and peer review statement has been added.

**Contributors** MM, YZ, JZ, HY, XY and XQ acquired data, drafted the manuscript, and critically revised the manuscript for important intellectual content. MM, YZ, HY, PW, YH and YRH performed in vitro and in vivo assays. MM, HY and XY analyzed and interpreted data and statistical analysis. YZ, YH and LK provided technical or material support. MM, XY, YH and LK approved the final version of the manuscript.

**Funding** This work was supported by the National Nature Science Foundation of China (Grant Nos. 81972213 for MM, Nos. 81702388 for YRH, Nos.81802503 for HY, Nos. 8117720 for KL), the Key University Science Research Project of Anhui Province (KJ2020A0594 for YZ, 180808SM271 for JZ), Shanghai Training and Support Program for Young Physician (for MMZ), Fudan University Shanghai Cancer Center for Outstanding Youth Scholars Foundation (YJYQ201803 for MMZ), Shanghai Sailing Program (18F1142700 for PW), Peak Training Program for Scientific Research of Yijishan Hospital, Wannan Medical College (GF2019T01 for KL, GF2019G15 for HY).

**Competing interests** None declared.

**Patient consent for publication** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available in a public, open access repository. It is available.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**REFERENCES**

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.
2. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016;66:115–32.
3. Salati M, Orsi G, Smyth E, et al. Gastric cancer: translating novels concepts into clinical practice. Cancer Treat Rev 2019;79:101889.
4. Fritz JM, Lenardo MJ. Development of immune checkpoint therapy for cancer. J Exp Med 2019;216:1244–54.
5. Saleh R, Eldord E. Acquired resistance to cancer immunotherapy: role of tumour-mediated immunosuppression. Semin Cancer Biol 2020;65:13–27.
6. Goldberg MS. Improving cancer immunotherapy through nanotechnology. Nat Rev Cancer 2019;19:587–602.
7. Hinshaw DC, Shveda LA. The tumor microenvironment Innately modulates cancer progression. Cancer Res 2019;79:4557–66.
8. Hill BS, Sarnella A, D’Avinio G, et al. Recruitment of stromal cells into tumour microenvironment promote the metastatic spread of breast cancer. Semin Cancer Biol 2020;60:202–13.
9. DeNardo DG, Ruthell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol 2019;19:369–82.
10. Wang H-C, Chen C-W, Yang C-L, et al. Tumor-Associated macrophages promote epigenetic silencing of gelsolin through DNA methyltransferase 1 in gastric cancer cells. Cancer Immunol Res 2017;5:885–97.
11. Harada K, Dong X, Estrella JS, et al. Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma. Gastric Cancer 2018;21:31–40.
12. Yamaguchi T, Fushida S, Yamamoto Y, et al. Tumor-associated macrophages of the M2 phenotype contribute to progression in gastric cancer with peritoneal dissemination. Gastric Cancer 2016;19:1052–65.
13. Chen D-P, Ning W-R, Jiang Z-Z, et al. Glycolytic activation of peritumoral monocytes fosters immune privilege via the FPFK3-PD-L1 axis in human hepatocellular carcinoma. J Hepatol 2019;71:333–43.
14. Divakaruni AS, Hisew WY, Minarieita L, et al. Etomoxir inhibits macrophage polarization by disrupting Coa homeostasis. Cell Metab 2018;28:490–503.
15. Langston PK, Nambu A, Jung J, et al. Glycerol phosphate shuttle enzyme GP2 regulates macrophage inflammatory responses. Nat Immunol 2019;20:1186–95.
16. Jones N, Vincent EE, Cronin JG, et al. Akt and STAS mediate naïve human CD4+ T-cell early metabolic response to TCR stimulation. Nat Commun 2019;10:2042.
17. Pacella I, Proocaccini C, Focaccietti C, et al. Fatty acid metabolism supports early glycolytic reprogramming required for dendritic cell immune responses. Cell Metab 2017;26:558–67.
18. Hansen IS, Krabbenland B, Bennik JH, et al. FcoRI co-stimulation converts human intestinal CD103+ dendritic cells into pro-inflammatory cells through glycolytic reprogramming. Nat Commun 2018:9:863.
19. Thwe PM, Pelgrom LR, Cooper R, et al. Cell-Intrinsic glycolysis metabolism supports early glycolytic reprogramming required for dendritic cell immune responses. Cell Metab 2017;26:558–67.
20. Jha AK, Huang SC-C, Serguschevich A, et al. Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. Immunity 2015;42:419–30.
21. Vitale I, Manic G, Coussens LM, et al. Macrophages and metabolism in the tumor microenvironment. Cell Metab 2019;30:36–50.
22. Shiraki N, Shiraki Y, Tsuyama T, et al. Methionine metabolism regulates maintenance and differentiation of human pluripotent stem cells. Cell Metab 2014;19:780–94.
23. Chandrasekaran S, Zhang J, Sun Z, et al. Comprehensive mapping of pluripotent stem cell metabolism using dynamic genome-scale network modeling. Cell Rep 2017;21:2965–77.
Wang Z, Yip LY, Lee JHJ, et al. Methionine is a metabolic dependency of tumor-initiating cells. *Nat Med* 2019;25:825–37.

Frau M, Foo F, Pascale RM. Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis. *J Hepatol* 2013;59:830–41.

Maldonado LY, Arsene D, Mato JM, et al. Methionine adenosyltransferases in cancers: mechanisms of dysregulation and implications for therapy. *Exp Biol Med* 2018;243:107–17.

Zhang T, Zheng Z, Liu Y, et al. Overexpression of methionine adenosyltransferase II alpha (MAT2A) in gastric cancer and induction of cell cycle arrest and apoptosis in SGC-7901 cells by shRNA-mediated silencing of MAT2A gene. *Acta Histochem* 2013;115:48–55.

Covarrubias AJ, Aksoylar HI, Yu J, et al. Akt- mTORC1 signaling regulates Acly to integrate metabolic input to control of macrophage activation. *Elife* 2016;5:e11612.

Lauterbach MA, Hanke JE, Serefidou M, et al. Toll-like receptor signaling rewires macrophage metabolism and promotes histone acetylation via ATP-citrate lyase. *Immunity* 2019;51:997–1011.

Kimball AS, Davis FM, denDekker A, et al. The histone methyltransferase Setdb2 modulates macrophage phenotype and uric acid production in diabetic wound repair. *Immunity* 2019;51:258–71.

Li T, Garcia-Gomez A, Morante-Palacios O, et al. SIRT1/2 orchestrate acquisition of DNA methylation and loss of histone H3 activating marks to prevent premature activation of inflammatory genes in macrophages. *Nucleic Acids Res* 2020;48:665–81.

Kuang D-M, Xiao X, Zhao Q, et al. B7-H1-expressing antigen-presenting cells mediate polarization of protumorigenic Th22 subsets. *J Clin Invest* 2014;124:4657–67.

Ma M, Zhang Y, Weng M, et al. IncRNA GCAWKR promotes gastric cancer development by scaffolding the chromatin modification factors WDR5 and KAT2A. *Mol Ther* 2018;26:2658–68.

Xiang H, Ramlil CP, Hai J, et al. Cancer-associated fibroblasts promote immunosuppression by inducing ROS-generating monocytic MDSCs in lung squamous cell carcinoma. *Cancer Immunol Res* 2020;8:436–50.

Eckert MA, Coscia F, Chryplewicz A, et al. Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. *Nature* 2019;569:723–8.

Sinclair LV, Howden AJ, Brenes A, et al. Antigen receptor control of methionine metabolism in T cells. *Elife* 2019;8:e44210.

Zhang W, Sviripa V, Chen X, et al. Fluorinated N,N-dialkylaminostilbenes repress colon cancer by targeting methionine S-adenosyltransferase 2A. *ACS Chem Biol* 2013;8:796–803.

Wang W, Marinis JM, Beal AM, et al. Rip1 kinase drives macrophage-mediated adaptive immune tolerance in pancreatic cancer. *Cancer Cell* 2018;34:757–74.

Sanderson SM, Gao X, Dai Z, et al. Methionine metabolism in health and cancer: a nexus of diet and precision medicine. *Nat Rev Cancer* 2019;19:625–37.

Mentch SJ, Mehrmohamadi M, Huang L, et al. Histone methylation dynamics and gene regulation occur through the sensing of one-carbon metabolism. *Cell Metab* 2015;22:661–73.

Bai J, Gao Y, Chen L, et al. Identification of a natural inhibitor of methionine adenosyltransferase 2A regulating one-carbon metabolism in keratinocytes. *EBioMedicine* 2019;39:575–90.

Yu W, Wang Z, Zhang K, et al. One-carbon metabolism supports S-adenosylmethionine and histone methylation to drive inflammatory macrophages. *Mol Cell* 2019;75:1147–60.

Shima H, Matsumoto M, Ishigami Y, et al. S-Adenosylmethionine Synthesis Is Regulated by Selective N6-Adenosine Methylation and mRNA Degradation Involving METTL16 and YTHDC1. *Cell Rep* 2017;21:3554–63.

Doxtader KA, Wang P, Scarborough AM, et al. Structural basis for regulation of METTL16, an S-adenosylmethionine homeostasis factor. *Mol Cell* 2018;71:1001–11.

Roy DG, Chen J, Mamane V, et al. Methionine metabolism shapes T helper cell responses through regulation of epigenetic reprogramming. *Cell Metab* 2020;31:250–66.